{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["82(1)"],"submitter":["Ayton S"],"pubmed_abstract":["<h4>Importance</h4>Interventions that substantially slow neurodegeneration are needed to address the growing burden of Alzheimer disease (AD) to societies worldwide. Elevated brain iron observed in AD has been associated with accelerated cognitive decline and may be a tractable drug target.<h4>Objective</h4>To investigate whether the brain-permeable iron chelator deferiprone slows cognitive decline in people with AD.<h4>Design, setting, and participants</h4>This phase 2, double-masked, placebo-controlled randomized clinical trial of 12-month duration was conducted at 9 sites in Australia between August 2, 2018, and April 1, 2023. Patients older than 54 years with amyloid-confirmed mild cognitive impairment or early AD (a Mini-Mental State Examination score of 20 or higher) were screened. R"],"journal":["JAMA neurology"],"pagination":["11-18"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11536302"],"repository":["biostudies-literature"],"pubmed_title":["Deferiprone in Alzheimer Disease: A Randomized Clinical Trial."],"pmcid":["PMC11536302"],"pubmed_authors":["Spino M","Bush AI","Maruff P","Devos D","Barton D","Rowe C","Schofield PW","Brew B","Fradette C","Wagen A","Goh AMY","Woodward M","Salvado O","Ayton S","Clarnette R","Brodtmann A","Fazlollahi A","Kalinowski P","Tricta F","O'Brien TJ","Kyndt C","Desmond P","Lai R","Lim YY","Ellis KA","Williams R"],"additional_accession":[]},"is_claimable":false,"name":"Deferiprone in Alzheimer Disease: A Randomized Clinical Trial.","description":"<h4>Importance</h4>Interventions that substantially slow neurodegeneration are needed to address the growing burden of Alzheimer disease (AD) to societies worldwide. Elevated brain iron observed in AD has been associated with accelerated cognitive decline and may be a tractable drug target.<h4>Objective</h4>To investigate whether the brain-permeable iron chelator deferiprone slows cognitive decline in people with AD.<h4>Design, setting, and participants</h4>This phase 2, double-masked, placebo-controlled randomized clinical trial of 12-month duration was conducted at 9 sites in Australia between August 2, 2018, and April 1, 2023. Patients older than 54 years with amyloid-confirmed mild cognitive impairment or early AD (a Mini-Mental State Examination score of 20 or higher) were screened. R","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2026-06-05T11:34:48.849Z","creation":"2026-05-16T03:13:12.202Z"},"accession":"S-EPMC11536302","cross_references":{"pubmed":["39495531"],"doi":["10.1001/jamaneurol.2024.3733"]}}